Exagen Inc Dossier
Qualitative Analysis
Business overview
Exagen Inc. (Nasdaq: XGN) is a commercial-stage diagnostics company dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune and rheumatic diseases. Headquartered in Vista, California, the company specializes in the design, development, and commercialization of advanced testing products under its flagship AVISEu0000 brand. Exagen's proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology assesses the activation of the complement system, a biological pathway widely implicated in complex autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead product, AVISEu0000 CTD, provides clinicians with a highly accurate, differential diagnosis tool to distinguish connective tissue diseases with overlapping symptoms.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Enhancing the flagship AVISE CTD platform with novel biomarkers, including the commercial launch of anti-PAD4 and T-Cell biomarkers to address seronegative diagnostic gaps in rheumatoid arthritis and systemic lupus erythematosus.
Expected impact: Aims to drive volume growth, increase average selling price (ASP), and improve overall gross margins.
Expanding sales territories from 40 to 45, upgrading commercial talent, and improving sales productivity to deepen relationships with rheumatology clinics.
Expected impact: Aims to capture market share and drive high single-digit volume growth for the full year 2026.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Exagen with a worldwide exclusive license to develop novel patented biomarkers (including Tenascin-C) for the non-invasive therapeutic management and risk stratification of patients with lupus nephritis.
Terms: Terms of the license agreement were not publicly disclosed.